Head – Global Oncology Pipeline - Medical Affairs
$248k - $471.5k/yr+ Long-term incentive program
Expert
Master's, MD
San Francisco, CA, USA+2 moreMore locations: Florham Park, NJ, USA | Mettawa, IL, USA
HybridHybrid: 3 days per week in office. Travel domestically and internationally up to 25–30%.
Biology & Biotech
About the job
Requirements
- An M.D. or equivalent advanced degree in a relevant scientific discipline, such as oncology or hematology.
- At least 15 years of experience in the pharmaceutical or biotechnology industry, focused on oncology, specifically hematology.
- Expertise in clinical development, regulatory requirements, and commercialization of oncology therapies.
- Leadership experience in medical affairs, including managing direct and indirect reports, cross-functional teams, and influencing strategic direction at the senior executive level.
- Scientific knowledge of solid tumor biology, clinical trial design, biomarker development, and emerging treatment modalities such as immuno-oncology, targeted therapies, and precision medicine.
- Ability to collaborate cross-functionally with clinical development, regulatory, commercial, and other business functions.
- Experience presenting complex scientific information to technical and non-technical stakeholders.
- Ability to travel domestically and internationally up to 25–30%.
Responsibilities
- Lead global pipeline medical affairs strategy and develop differentiation across the lifecycle, using market insights to shape therapeutic-area pipeline strategy.
- Shape initial value and evidence strategy and initiate evidence-generation plans using insights from payors, patients, and physicians.
- Direct the pipeline execution team to ensure strategy is carried through to enterprise research medical science liaisons.
- Collaborate with counterparts in international therapeutic areas, global therapeutic-area business units, and development.
- Represent the therapeutic area in pipeline governance when aligned with the therapeutic-area business unit head.
- Work with operations and medical engagement teams to operationalize pipeline strategy.
- Lead and oversee pipeline, including business development, medical, value, and evidence strategy development across disease areas and indications or brands up to 24–36 months before launch, serving U.S. and international markets.
- Drive differentiation of medical, value, and evidence strategy from discovery using insights from U.S. and international markets.
- Coordinate across therapeutic areas so their pipeline strategies form a coherent enterprise pipeline strategy.
- Ensure health care professional, patient, and payor insights inform development programs to accelerate and differentiate clinical and commercialization strategies, including streamlined patient data collection and patient finding.
- Co-create brand strategy for all assets and embed U.S. and international market insights in brand strategy.
- Represent medical affairs in pipeline-related governance as the primary contact for commercial and development counterparts.
- Serve as the final decision maker before the business unit head for pipeline-related strategy and decisions.
- Manage pipeline resources and redirect the pipeline team toward enterprise-critical assets across the lifecycle, starting as early as discovery.
- Ensure effective handover to U.S. and international inline and launch teams, onboarding relevant therapeutic areas to share pipeline strategy insights and approaches and minimize duplicated effort.
- Lead cross-functional gap assessment and integrated evidence planning in collaboration with value and evidence teams.
- Define enterprise research medical science liaison strategy in the U.S. and affiliates using pipeline insights to develop priorities and shape tactical plans.
- Coordinate with the U.S. medical engagement pipeline execution group to drive execution.
- Collaborate with U.S. medical engagement to track impact-focused key performance indicators and reshape pipeline strategy based on impact or best practices.
Desired Qualifications
- Familiarity with advanced cancer treatment modalities such as chimeric antigen receptor T-cell therapies, combination therapies, and immuno-oncology.
- A strong publication and scientific communication record in oncohematology, including contributions to peer-reviewed journals and major oncology conferences.
- Experience managing global medical affairs activities across multiple geographic regions, with a focus on global strategy and the U.S. region.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget